Clinical TrialJun 29, 2026, 07:36 AM
BrainsWay Deep TMS Shows Positive Data for Comorbid PTSD & MDD
AI Summary
BrainsWay Ltd. announced positive real-world data from the largest study of its Deep TMS™ technology in patients with comorbid Post-Traumatic Stress Disorder (PTSD) and Major Depressive Disorder (MDD). The study, involving 462 patients, showed significant improvements, with 83.5% experiencing a response in PTSD symptoms and a 66.6% response rate in depression symptoms. While these findings are promising, Deep TMS is not yet FDA cleared for PTSD or comorbid PTSD and MDD.
Key Highlights
- Study evaluated 462 patients with comorbid PTSD and MDD from 11 clinical sites.
- 83.5% of patients experienced a response (reduction in PTSD symptoms of ≥50%) following Deep TMS.
- Mean reduction in PTSD symptoms (PCL-5 scores) was 52%.
- 66.6% response rate for depression symptoms (reduction of ≥50%) was observed.
- Patients experienced a 27.3% remission rate for depression symptoms.
- Mean reduction in depression symptoms (PHQ-9 scores) was 50%.
- Deep TMS is not currently FDA cleared for the treatment of PTSD and/or comorbid PTSD and MDD.
Price Impact
More from BWAY